Clinical Trial Update: ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial [Phase 1, Phase 2]

View source ↗

Summary

This entry covers ALLG AMLM26 INTERCEPT, a multi-arm Phase 1/2 precision-based platform trial at MD Anderson Cancer Center evaluating novel therapies to prevent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: AML | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING